Jan 17,2019

Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has substantially advanced the use-case for SugarBEAT® to improve management of glucose levels by spending more time in range.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 28,2019

Dexcom G6 users can ask Siri to read their glucose level

For folks managing their diabetes with Dexcom, Siri can now answer one more question: What is my glucose level? This morning Dexcom announced a slew of new companion app features for the Dexcom G6 continuous glucose monitoring system, including the ability for Siri to read a user’s glucose level out loud and display graphs directly on the lock screen.

PRODUCT

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 03,2019

Roche expands access for people with diabetes to innovative long-term continuous glucose monitoring technology with unique 6 months wear time

Roche announced today the extension of the collaboration and distribution agreement with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a longterm, implantable CGM system for people with diabetes. Under the terms of the agreement, Roche will continue its role as Senseonics’ exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel. The new agreement is expanded to include 17 additional countries including Brazil, Russia, India and China as well as selected markets in the Asia Pacific and Latin American regions and will run through January 31, 2021.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 07,2019

Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

Nemaura Medical Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, today announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 19,2019

PKvitality Continuous Glucose Monitor K’Watch is Exciting

The PKvitality team wants to disrupt the existing CGM market. Rather than making incremental improvements they have reimagined the CGM experience. Their goal is to significantly expand the use of CGM for people with T1D and T2D. The smartwatch-based approach provides a discrete and pain-free solution that keeps any complexity in the watch itself. This enables the sensor to be radically lower in cost.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2019

NEW REAL-WORLD EVIDENCE ANALYSIS OF NEARLY HALF A MILLION FREESTYLE® LIBRE SYSTEM USERS SHOWS HIGHER RATES OF SCANNING IMPROVES GLUCOSE CONTROL

Abbott today announced data from three real-world evidence studies that provide a comprehensive look at the global use of the FreeStyle® Libre flash glucose monitoring system and its impact on health outcomes for people living with diabetes. The new real-world evidence analyses, which for the first time included data from the United States, highlighted key user benefits, including reduction in prolonged hypoglycemia and better glucose control when using both the glucose level and trend arrow during meal times. The data was presented today at the 12th Advanced Technologies & Treatments for Diabetes (ATTD) meeting in Berlin.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 25,2019

Medtronic Wraps Up Scientific Data Presentations at the Advanced Technologies and Treatments for Diabetes International Conference

At this year's conference, the Diabetes Group at Medtronic presented a range of scientific data focusing on the company's latest MiniMed(TM) 670G system and its exclusive SmartGuard(TM) technology, including new pediatric data and the importance of Time in Range, defined as the percentage of time people with diabetes spend between the glucose range of 70-180 mg/dL (3.9-10 mmol/L).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 05,2019

Eversense CGM to integrate with Glooko

This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 25,2019

Senseonics launches program for low-cost Eversense CGM systems

On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 01,2019

Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings

Deidentified glucose results from 6802 flash glucose monitors were analyzed after dividing into high, medium and low-risk groups based on tertiles of time spent in hypoglycemia (min/day <70 mg/dL) or hyperglycemia (hours/day >240 mg/dL). Groups were further subdivided into tertiles of glucose scanning frequency and glycemic measures analyzed in the first 14 days and over 6 months.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM